Prolonged progression-free survival in a patient with triple-negative breast cancer metastatic to the liver after chemotherapy and local radiation therapy

Clin Breast Cancer. 2014 Apr;14(2):e61-4. doi: 10.1016/j.clbc.2013.11.007. Epub 2013 Nov 21.

Authors

Bryan Chang¹, Joseph Sokhn², Edward James³, Maysa Abu-Khalaf³

Affiliations

¹ Department of Radiation Oncology, Yale University School of Medicine, New Haven, CT. Electronic address: bryan.chang@yale.edu.
² Department of Medicine, Yale University School of Medicine, New Haven, CT.
³ Section of Medical Oncology, Yale Cancer Center, Yale University School of Medicine, New Haven, CT.

PMID: 24373644
DOI: 10.1016/j.clbc.2013.11.007

No abstract available

Keywords: Chemotherapy; Liver metastasis; Radiation; Stereotactic body radiation therapy; Triple negative breast cancer.

Publication types

Case Reports

MeSH terms

Adult
Antibodies, Monoclonal, Humanized / administration & dosage
Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
Bevacizumab
Carcinoma, Intraductal, Noninfiltrating / mortality*
Carcinoma, Intraductal, Noninfiltrating / pathology
Carcinoma, Intraductal, Noninfiltrating / therapy
Chemoradiotherapy*
Female
Humans
Liver Neoplasms / mortality*
Liver Neoplasms / pathology
Liver Neoplasms / secondary
Middle Aged
Neoplasm Grading
Paclitaxel / administration & dosage
Prognosis
Survival Rate
Triple Negative Breast Neoplasms / mortality*
Triple Negative Breast Neoplasms / pathology
Triple Negative Breast Neoplasms / therapy

Substances

Antibodies, Monoclonal, Humanized
Bevacizumab
Paclitaxel